Cameco (NYSE:CCJ - Get Free Report) TSE: CCO issued its earnings results on Tuesday. The basic materials company reported $0.34 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.05, Zacks reports. Cameco had a return on equity of 9.35% and a net margin of 17.00%.The firm had revenue of $607.49 million for the quarter, compared to analysts' expectations of $598.63 million. During the same quarter last year, the firm earned $0.16 earnings per share. The firm's revenue for the quarter was up 7.1% compared to the same quarter last year.
Here are the key takeaways from Cameco's conference call:
- Cameco says nuclear momentum is structural, with governments focused on execution and AP1000 technology emerging as the deployment-ready benchmark that should drive long-term fuel demand.
- Progress continues on Westinghouse negotiations with the U.S. government (DOC and DOE tracks), with company involvement in supply‑chain standing‑up and the possibility of up to ~20 U.S. reactors being discussed, though definitive agreements are still in progress.
- Q1 results were in line with expectations and the company left its full-year 2026 guidance unchanged; quarter-over‑quarter gains were mainly timing and higher uranium prices rather than a structural change.
- Operations remain on plan—Canadian production tracking to guidance, JV Inkai back to planned production, and a planned extended Q3 Key Lake shutdown to tie in infrastructure; some supply‑chain cost pressures (e.g., acid) are being monitored but not expected to materially impact 2026.
- Cameco is actively managing supply via inventory and product loans (now over 4 million pounds borrowed) and advancing Global Laser Enrichment (at TRL 6) as a potential Western enrichment/conversion source, supporting long‑term supply diversification.
Cameco Stock Up 8.1%
Shares of NYSE CCJ traded up $9.27 during midday trading on Wednesday, reaching $123.73. 3,760,760 shares of the company's stock were exchanged, compared to its average volume of 3,909,235. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.68 and a current ratio of 2.47. The stock has a market capitalization of $53.89 billion, a PE ratio of 127.56, a price-to-earnings-growth ratio of 2.19 and a beta of 1.04. Cameco has a 52-week low of $47.87 and a 52-week high of $135.24. The business's fifty day moving average price is $114.81 and its two-hundred day moving average price is $105.52.
Analyst Ratings Changes
A number of research analysts recently weighed in on CCJ shares. Raymond James Financial reiterated an "outperform" rating on shares of Cameco in a report on Wednesday, January 14th. William Blair initiated coverage on Cameco in a research report on Monday, April 20th. They issued an "outperform" rating on the stock. Glj Research restated a "buy" rating and set a $171.20 price objective (up from $100.00) on shares of Cameco in a research note on Wednesday, February 18th. Zacks Research cut Cameco from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 18th. Finally, Scotiabank restated an "outperform" rating and set a $175.00 price objective on shares of Cameco in a research note on Wednesday. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $153.13.
Read Our Latest Research Report on CCJ
Trending Headlines about Cameco
Here are the key news stories impacting Cameco this week:
Hedge Funds Weigh In On Cameco
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Morgan Stanley boosted its stake in Cameco by 7.0% in the fourth quarter. Morgan Stanley now owns 4,978,333 shares of the basic materials company's stock valued at $455,468,000 after acquiring an additional 323,693 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Cameco by 7.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,911,918 shares of the basic materials company's stock worth $267,181,000 after purchasing an additional 200,561 shares in the last quarter. Progeny 3 Inc. raised its holdings in Cameco by 5.4% during the second quarter. Progeny 3 Inc. now owns 2,442,732 shares of the basic materials company's stock worth $181,324,000 after purchasing an additional 124,600 shares in the last quarter. Amundi raised its holdings in Cameco by 5.9% during the fourth quarter. Amundi now owns 2,349,070 shares of the basic materials company's stock worth $214,916,000 after purchasing an additional 130,436 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in Cameco by 7,481.3% during the fourth quarter. Marshall Wace LLP now owns 1,752,571 shares of the basic materials company's stock worth $160,343,000 after purchasing an additional 1,729,454 shares in the last quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
Cameco Company Profile
(
Get Free Report)
Cameco Corporation NYSE: CCJ is a leading producer of uranium and a supplier to the global nuclear power industry. Headquartered in Saskatoon, Saskatchewan, Canada, the company is engaged in the exploration, mining, milling and sale of uranium concentrate, commonly known as yellowcake, which is used as fuel for nuclear reactors. Cameco also participates in services and activities that support the front end of the nuclear fuel cycle, including processing and marketing of uranium to utilities under long‑term and spot contracts.
The company's operations have historically centered in Canada and the United States, where it operates and develops uranium mining and processing properties.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cameco, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cameco wasn't on the list.
While Cameco currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.